Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272311 · ClinicalTrials.gov registry record · Phase 4
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
A Phase 4 study of Cardiovascular Diseases and Atherosclerosis, sponsored by Florida Atlantic University.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT00272311 is a Phase 4 study of Cardiovascular Diseases and Atherosclerosis that has completed, run by Florida Atlantic University. The registered enrollment target is 70 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00272311, a Phase 4 study of Cardiovascular Diseases and Atherosclerosis, has completed, sponsored by Florida Atlantic University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
Conditions Studied
Interventions
- DRUG Aspirin
Study Locations (1)
Maryland
- HeartDrug Research, LLC - Towson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272311
The ClinicalTrials.gov registry entry for NCT00272311 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Florida Atlantic University, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.
NCT00272311 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00272311 about?
NCT00272311 is a clinical study titled "Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome". The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
What is the current status of trial NCT00272311?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2006-10. Estimated completion is 2009-01.
What conditions does trial NCT00272311 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Atherosclerosis, Metabolic Syndrome X.
What interventions are being tested in trial NCT00272311?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT00272311?
This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00272311 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.